A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Item 1. Business We are a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases. We currently sell three commercial stage drug products, FIRDAPSE® (amifampridine), AGAMREE® (vamorolone), and FYCOMPA® (perampanel). We are also currently seeking to further expand our product portfolio, with a focus on acquiring the rights to immediately and near-term accretive assets to treat rare (orphan) diseases across therapeutic areas, including clinical-stage opportunities with established proof of concept. With an unwavering patient focus embedded in everything we do, we are committed to providing innovative, best-in-class medications with the hope of making a meaningful positive impact on those affected by these conditions. Currently, we have a total of 58 field personnel supporting FIRDAPSE® and AGAMREE®.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 589M | 589M | 492M | 398M | 214M | 141M |
| Net Income | 214M | 214M | 164M | 71M | 83M | 39M |
| EPS | $1.68 | $1.68 | $1.31 | $0.63 | $0.75 | $0.37 |
| Free Cash Flow | 209M | 209M | 239M | 143M | 116M | 59M |
| ROIC | 78.6% | 78.6% | 17.4% | 51.3% | 1364.8% | 160.0% |
| Gross Margin | 85.2% | 85.2% | 86.0% | 86.9% | 83.9% | 84.5% |
| Debt/Equity | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.02 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | 258M | 258M | 195M | 87M | 102M | 52M |
| Operating Margin | 43.8% | 43.8% | 39.7% | 21.8% | 47.5% | 37.2% |
| ROE | 22.5% | 25.5% | 29.4% | 20.7% | 32.8% | 21.0% |
| Shares Outstanding | 128M | 128M | 125M | 113M | 111M | 107M |
CATALYST PHARMACEUTICALS, INC. passes 7 of 9 quality checks, indicating strong fundamentals.
CATALYST PHARMACEUTICALS, INC. trades at 15.6x trailing earnings, compared to its 15-year median P/E of 16.4x, suggesting it is currently Fair relative to its historical range. On a free-cash-flow basis, the stock trades at 15.3x vs a median of 12.7x. The company's 5-year average ROIC is 76.8% with a gross margin of 85.3%. Total shareholder yield (buybacks) is 0.8%. At current prices, the estimated annualized return to fair value is +43.4%.
CATALYST PHARMACEUTICALS, INC. (CPRX) has a current P/E ratio of 15.6, compared to its historical median P/E of 16.4. The stock is currently considered Fair based on its historical valuation range.
CATALYST PHARMACEUTICALS, INC. (CPRX) has a 5-year average return on invested capital (ROIC) of 76.8%. This indicates strong capital allocation and a potential competitive advantage.
CATALYST PHARMACEUTICALS, INC. (CPRX) has a market capitalization of $3.3B. It is classified as a mid-cap stock.
CATALYST PHARMACEUTICALS, INC. (CPRX) does not currently pay a regular dividend. However, the company returns capital to shareholders through share buybacks, with a buyback yield of 0.76%.
Based on historical P/E analysis, CATALYST PHARMACEUTICALS, INC. (CPRX) appears fair. The current P/E of 15.6 is 5% below its historical median of 16.4. The estimated fair value CAGR (P/E method) is 23.5%.
CATALYST PHARMACEUTICALS, INC. (CPRX) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
CATALYST PHARMACEUTICALS, INC. (CPRX) reported annual revenue of $589 million in its most recent fiscal year, based on SEC EDGAR filings.
CATALYST PHARMACEUTICALS, INC. (CPRX) has a net profit margin of 36.4%. This is a strong margin indicating high profitability.
CATALYST PHARMACEUTICALS, INC. (CPRX) generated $209 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
CATALYST PHARMACEUTICALS, INC. (CPRX) has a debt-to-equity ratio of 0.00. This indicates a conservatively financed balance sheet.
CATALYST PHARMACEUTICALS, INC. (CPRX) reported earnings per share (EPS) of $1.68 in its most recent fiscal year.
CATALYST PHARMACEUTICALS, INC. (CPRX) has a return on equity (ROE) of 25.5%. This indicates the company generates strong returns for shareholders.
CATALYST PHARMACEUTICALS, INC. (CPRX) has a 5-year average gross margin of 85.3%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 16 years of financial data for CATALYST PHARMACEUTICALS, INC. (CPRX), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
CATALYST PHARMACEUTICALS, INC. (CPRX) has a book value per share of $7.48, based on its most recent annual SEC filing.